



TNK Calculations:

Maximum dose for acute ischemic stroke is 25 mg

Mixing: TNK comes in a kit – follow manufacturer's instructions

- Total concentration of TNK per vial is 5mg/ml
- Dose in mg / 5 mg/ml = Volume

Total dose to administer: 0.25mg x kg = Total dose mg/kg (Max dose=25mg)

- Draw up total dose in a 5 ml syringe
- Ex. 0.25 mg x 75.5 kg = 18.9 mg (round to nearest 10th of an ml)

Calculate bolus dose: Take dose desired & divide it by total mg & multiply by mls

• $18.9 \text{ mg} \div 50 \text{ mg x } 10 \text{ ml} = 3.8 \text{ ml}$ (round to nearest 10th of an ml)

Supplies needed:

THROMBOLYTIC THERAPY:

TNK-TNK 50 mg kit containing lyophilized powder, diluent, needle, syringe & alcohol prep

TNK Administration & Reconstitution:

RECONSTITUTION AND ADMINISTRATION

See Prescribing Information for further directions.

(Use aseptic technique throughout.)



 WITHDRAW 10 mL of Sterile Water for Injection, USP, using the 10 mL BD[®] Syringe with BD Twinpak[™] Dual Cannula Device included in the kit. See TNKase Package Insert for instructions on use of the dual cannula device.



 INJECT entire contents into the TNKase vial, directing the diluent at the powder. Slight foaming upon reconstitution is not uncommon. Let stand undisturbed for several minutes to allow bubbles to dissipate.



3. GENTLY SWIRL until contents are completely dissolved. DO NOT SHAKE. Solution should be colorless or pale yellow and transparent. USE UPON RECONSTITUTION. If not used immediately, refrigerate solution at 2°C to 8°C (36°F to 46°F) and use within 8 hours. DO NOT FREEZE.



4. WITHDRAW the appropriate volume of solution based on patient weight. (See Dosing Information.) The recommended total dose should not exceed 50 mg. Any unused solution should be discarded.



- FLUSH a dextrose-containing line with a salinecontaining solution prior to and following administration. (Precipitation may occur when TNKase is administered in an intravenous [IV] line containing dextrose.)
- ADMINISTER as an IV BOLUS over 5 seconds.

Always refer to MV-02-053 stroke policy for the most current, up to date information Tenecteplase [Package Insert]. San Francisco, CA. Genetech, Inc. 2018.